Valesca Bukur

TL;DR: The first-in-human application of individualized mutanome vaccines in melanoma is reported, demonstrating that individual mutations can be exploited and opening a path to personalized immunotherapy for patients with cancer.

TL;DR: In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.

TL;DR: It is shown, for two applications of mRNA therapeutics, namely, the delivery of vaccine antigens in order to mount T cell immune responses and the introduction of reprogramming factors into differentiated cells inorder to induce pluripotency, that mRNAs tagged with the 3' UTR elements discovered in this study outperform those with commonly used 3'UTRs.

TL;DR: A novel model faithfully recapitulating some key human GBM characteristics, including low mutational load, is described, which suggests that SB28 may represent a treatment-resistant malignancy likely to mirror responses of many human tumors.

TL;DR: An integrated map of the genome, transcriptome, and immunome of 4T1 cells supports the rational design of mode-of-action studies for pre-clinical evaluation of targeted immunotherapies and provides evidence for 6-thioguanine resistance.